LadRx Corporation Banner Image

LadRx Corporation

  • Ticker LADXD
    Exchange OTC More
  • Industry Biotechnology More
  • Sector Healthcare More
LadRx Corporation Logo Image
  • 1-10 Employees
  • Based in Los Angeles, California
LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer. LadRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, LadRx’s drug candidate, arimoclomolMore, was sold to Orphazyme A/S (now Zevra Therapeutics) in exchange for milestone payments and royalties. Zevra is developing arimoclomol and is currently focused on Niemann-Pick disease Type C (NPC).
4.8 / 5.0 (87)

LadRx Corporation reports have an aggregate usefulness score of 4.8 based on 87 reviews.

LadRx Corporation

Most Recent Annual Report

LadRx Corporation
MOST RECENT 2023 Annual Report and Form 10K

LadRx Corporation does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

LadRx Corporation Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!